| 1 |
Wang L, Liang C, Chen P, Cao Y, Zhang Y. Effect of antidepressants on psychological comorbidities, disease activity, and quality of life in inflammatory bowel disease: a systematic review and meta-analysis. Therap Adv Gastroenterol 2023;16:17562848231155022. [PMID: 36895280 DOI: 10.1177/17562848231155022] [Reference Citation Analysis]
|
| 2 |
Bauer N, Löffler C, Öznur Ö, Uecker C, Keil T, Langhorst J. Mind-body-medicine and comprehensive lifestyle-modification in patients with Crohn's disease—Feasibility of a randomized controlled trial under pandemic circumstances. Front Integr Neurosci 2022;16:960301. [DOI: 10.3389/fnint.2022.960301] [Reference Citation Analysis]
|
| 3 |
Monmousseau F, Mulot L, Rusch E, Picon L, Laharie D, Fotsing G, Gargot D, Charpentier C, Buisson A, Trang-Poisson C, Dib N, DES Garets V, Brunet-Houdard S, Aubourg A; COQC-PIT Study Group. Predictors of each quality of life dimension in Crohn's disease patients initiating an anti-TNF treatment: differentiated effects of patient-, disease-, and treatment-related characteristics. Scand J Gastroenterol 2022;57:566-73. [PMID: 35188859 DOI: 10.1080/00365521.2021.2025419] [Reference Citation Analysis]
|
| 4 |
Dubinsky MC, Irving PM, Panaccione R, Naegeli AN, Potts-Bleakman A, Arora V, Shan M, Travis S. Incorporating patient experience into drug development for ulcerative colitis: development of the Urgency Numeric Rating Scale, a patient-reported outcome measure to assess bowel urgency in adults. J Patient Rep Outcomes 2022;6:31. [PMID: 35362902 DOI: 10.1186/s41687-022-00439-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 5 |
van Deen WK, Khalil C, Dupuy TP, Bonthala NN, Spiegel BMR, Almario CV. Assessment of inflammatory bowel disease educational videos for increasing patient engagement and family and friends' levels of understanding. Patient Educ Couns 2022;105:660-9. [PMID: 34154860 DOI: 10.1016/j.pec.2021.06.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 6 |
Calviño-Suárez C, Ferreiro-Iglesias R, Bastón-Rey I, Barreiro-de Acosta M. Role of Quality of Life as Endpoint for Inflammatory Bowel Disease Treatment. Int J Environ Res Public Health 2021;18:7159. [PMID: 34281095 DOI: 10.3390/ijerph18137159] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 7 |
Khalil C, Van Deen W, Dupuy T, Bonthala N, Almario C, Spiegel B. Developing Patient-Centered Inflammatory Bowel Disease-Related Educational Videos Optimized for Social Media: Qualitative Research Study. JMIR Med Educ 2020;6:e21639. [PMID: 33079065 DOI: 10.2196/21639] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 8 |
Kim J, Park S, Shin J. Patterns of Ulcerative Colitis Treatments and Factors Affecting the Prescribing of Systemic Corticosteroid using Health Insurance Claims Database. Korean J Clin Pharm 2020;30:102-112. [DOI: 10.24304/kjcp.2020.30.2.102] [Reference Citation Analysis]
|
| 9 |
Khalil C, Van Deen W, Dupuy T, Bonthala N, Almario C, Spiegel B. Developing Patient-Centered Inflammatory Bowel Disease–Related Educational Videos Optimized for Social Media: Qualitative Research Study (Preprint).. [DOI: 10.2196/preprints.21639] [Reference Citation Analysis]
|
| 10 |
Roda G, Chien Ng S, Kotze PG, Argollo M, Panaccione R, Spinelli A, Kaser A, Peyrin-Biroulet L, Danese S. Crohn's disease. Nat Rev Dis Primers 2020;6:22. [PMID: 32242028 DOI: 10.1038/s41572-020-0156-2] [Cited by in Crossref: 207] [Cited by in F6Publishing: 211] [Article Influence: 69.0] [Reference Citation Analysis]
|
| 11 |
Wall CL, McCombie AM, Gearry RB, Day AS. Newly Diagnosed Crohn's Disease Treated with Standard Care or Enteral Nutrition: Psychological Outcomes over 6 Months. Inflamm Intest Dis 2019;4:7-13. [PMID: 31172008 DOI: 10.1159/000497323] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 12 |
Christiansen LK, Lo B, Bendtsen F, Vind I, Vester-Andersen MK, Burisch J. Health-related quality of life in inflammatory bowel disease in a Danish population-based inception cohort. United European Gastroenterol J 2019;7:942-54. [PMID: 31428419 DOI: 10.1177/2050640619852532] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 13 |
Zhang D, Ren YB, Wei K, Hong J, Yang YT, Wu LJ, Zhang J, Shi Z, Wu HG, Ma XP. Herb-partitioned moxibustion alleviates colon injuries in ulcerative colitis rats. World J Gastroenterol 2018; 24(30): 3384-3397 [PMID: 30122878 DOI: 10.3748/wjg.v24.i30.3384] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 14 |
Fumery M, Singh S, Dulai PS, Gower-Rousseau C, Peyrin-Biroulet L, Sandborn WJ. Natural History of Adult Ulcerative Colitis in Population-based Cohorts: A Systematic Review. Clin Gastroenterol Hepatol 2018;16:343-356.e3. [PMID: 28625817 DOI: 10.1016/j.cgh.2017.06.016] [Cited by in Crossref: 210] [Cited by in F6Publishing: 209] [Article Influence: 42.0] [Reference Citation Analysis]
|
| 15 |
Almario CV, Keller MS, Chen M, Lasch K, Ursos L, Shklovskaya J, Melmed GY, Spiegel BMR. Optimizing Selection of Biologics in Inflammatory Bowel Disease: Development of an Online Patient Decision Aid Using Conjoint Analysis. Am J Gastroenterol 2018;113:58-71. [PMID: 29206816 DOI: 10.1038/ajg.2017.470] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 7.2] [Reference Citation Analysis]
|
| 16 |
Martinez B, Dailey F, Almario CV, Keller MS, Desai M, Dupuy T, Mosadeghi S, Whitman C, Lasch K, Ursos L, Spiegel BMR. Patient Understanding of the Risks and Benefits of Biologic Therapies in Inflammatory Bowel Disease: Insights from a Large-scale Analysis of Social Media Platforms. Inflamm Bowel Dis 2017;23:1057-64. [PMID: 28410343 DOI: 10.1097/MIB.0000000000001110] [Cited by in Crossref: 37] [Cited by in F6Publishing: 29] [Article Influence: 6.2] [Reference Citation Analysis]
|
| 17 |
Huppertz-Hauss G, Høivik ML, Jelsness-Jørgensen LP, Opheim R, Henriksen M, Høie O, Hovde Ø, Kempski-Monstad I, Solberg IC, Jahnsen J, Hoff G, Moum B, Bernklev T. Fatigue in a population-based cohort of patients with inflammatory bowel disease 20 years after diagnosis: The IBSEN study. Scand J Gastroenterol 2017;52:351-8. [PMID: 27852169 DOI: 10.1080/00365521.2016.1256425] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 6.2] [Reference Citation Analysis]
|
| 18 |
Sarid O, Slonim-Nevo V, Pereg A, Friger M, Sergienko R, Schwartz D, Greenberg D, Shahar I, Chernin E, Vardi H, Eidelman L, Segal A, Ben-Yakov G, Gaspar N, Munteanu D, Rozental A, Mushkalo A, Dizengof V, Abu-Freha N, Fich A, Odes S; Israeli IBD Research Nucleus (IIRN). Coping strategies, satisfaction with life, and quality of life in Crohn's disease: A gender perspective using structural equation modeling analysis. PLoS One 2017;12:e0172779. [PMID: 28245260 DOI: 10.1371/journal.pone.0172779] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 19 |
Chouliaras G, Margoni D, Dimakou K, Fessatou S, Panayiotou I, Roma-Giannikou E. Disease impact on the quality of life of children with inflammatory bowel disease. World J Gastroenterol 2017; 23(6): 1067-1075 [PMID: 28246481 DOI: 10.3748/wjg.v23.i6.1067] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 38] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 20 |
Carlsen K, Munkholm P, Burisch J. Evaluation of Quality of Life in Crohn’s Disease and Ulcerative Colitis: What Is Health-Related Quality of Life? Crohn's Disease and Ulcerative Colitis 2017. [DOI: 10.1007/978-3-319-33703-6_25] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 21 |
Hajaghamohammadi A, Keshavarzi B, Zargar A. Investigation of Effective Factors on the Quality of Life of Patients Suffering from Ulcerative Colitis in Remission. Biotech Health Sci 2016;Inpress. [DOI: 10.17795/bhs-41877] [Reference Citation Analysis]
|
| 22 |
Hajaghamohammadi AA, Keshavarzi B, Zargar A. Investigation of Effective Factors on the Quality of Life of Patients Suffering from Ulcerative Colitis in Remission. Biotech Health Sci 2016;S. [DOI: 10.5812/bhs-41877] [Reference Citation Analysis]
|
| 23 |
Jelsness-Jørgensen LP, Bernklev T, Moum B. Coexisting irritable bowel-like symptoms in inflammatory bowel disease in remission is associated with impaired social functioning and increased bodily pain. Gastroenterol Nurs. 2014;37:280-287. [PMID: 25078042 DOI: 10.1097/SGA.0000000000000055] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 24 |
Kawalec P, Moćko P, Pilc A, Radziwon-zalewska M, Malinowska-lipień I. Vedolizumab Compared with Certolizumab in the Therapy of Crohn Disease: A Systematic Review and Indirect Comparison. Pharmacotherapy 2016;36:861-9. [DOI: 10.1002/phar.1784] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 25 |
Huppertz-Hauss G, Lie Høivik M, Jelsness-Jørgensen LP, Henriksen M, Høie O, Jahnsen J, Hoff G, Moum B, Bernklev T. Health-related Quality of Life in Patients with Inflammatory Bowel Disease 20 Years After Diagnosis: Results from the IBSEN Study. Inflamm Bowel Dis 2016;22:1679-87. [PMID: 27206016 DOI: 10.1097/MIB.0000000000000806] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 26 |
Petkau JM, Eksteen B. Selective biologics for ulcerative colitis and Crohn's disease - clinical utility of vedolizumab. Biologics 2016;10:33-52. [PMID: 27022240 DOI: 10.2147/BTT.S71679] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 27 |
Burisch J, Munkholm P. Telemonitoring and Self-Care in Patients with IBD. Telemanagement of Inflammatory Bowel Disease 2016. [DOI: 10.1007/978-3-319-22285-1_7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 28 |
Alarhayem A, Achebe E, Logue AJ. Psychosocial Support of the Inflammatory Bowel Disease Patient. Surgical Clinics of North America 2015;95:1281-93. [DOI: 10.1016/j.suc.2015.08.005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 29 |
Gater A, Kitchen H, Heron L, Pollard C, Håkan-Bloch J, Højbjerre L, Hansen BB, Strandberg-Larsen M. Development of a conceptual model evaluating the humanistic and economic burden of Crohn's disease: implications for patient-reported outcomes measurement and economic evaluation. Expert Rev Pharmacoecon Outcomes Res 2015;15:643-56. [PMID: 25985850 DOI: 10.1586/14737167.2015.1045883] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 30 |
Wright EK, Kamm MA. Impact of drug therapy and surgery on quality of life in Crohn's disease: a systematic review. Inflamm Bowel Dis 2015;21:1187-94. [PMID: 25895008 DOI: 10.1097/MIB.0000000000000271] [Cited by in Crossref: 51] [Cited by in F6Publishing: 49] [Article Influence: 6.4] [Reference Citation Analysis]
|
| 31 |
Huppertz-Hauss G, Høivik ML, Langholz E, Odes S, Småstuen M, Stockbrugger R, Hoff G, Moum B, Bernklev T. Health-related quality of life in inflammatory bowel disease in a European-wide population-based cohort 10 years after diagnosis. Inflamm Bowel Dis 2015;21:337-44. [PMID: 25569735 DOI: 10.1097/MIB.0000000000000272] [Cited by in Crossref: 45] [Cited by in F6Publishing: 39] [Article Influence: 5.6] [Reference Citation Analysis]
|
| 32 |
Burisch J, Weimers P, Pedersen N, Cukovic-Cavka S, Vucelic B, Kaimakliotis I, Duricova D, Bortlik M, Shonová O, Vind I, Avnstrøm S, Thorsgaard N, Krabbe S, Andersen V, Dahlerup JF, Kjeldsen J, Salupere R, Olsen J, Nielsen KR, Manninen P, Collin P, Katsanos KH, Tsianos EV, Ladefoged K, Lakatos L, Ragnarsson G, Björnsson E, Bailey Y, O'Morain C, Schwartz D, Odes S, Valpiani D, Boni MC, Jonaitis L, Kupcinskas L, Turcan S, Barros L, Magro F, Lazar D, Goldis A, Nikulina I, Belousova E, Fernandez A, Sanroman L, Almer S, Zhulina Y, Halfvarson J, Arebi N, Diggory T, Sebastian S, Lakatos PL, Langholz E, Munkholm P; EpiCom-group. Health-related quality of life improves during one year of medical and surgical treatment in a European population-based inception cohort of patients with inflammatory bowel disease--an ECCO-EpiCom study. J Crohns Colitis 2014;8:1030-42. [PMID: 24560877 DOI: 10.1016/j.crohns.2014.01.028] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 4.8] [Reference Citation Analysis]
|
| 33 |
van der Have M, van der Aalst KS, Kaptein AA, Leenders M, Siersema PD, Oldenburg B, Fidder HH. Determinants of health-related quality of life in Crohn's disease: a systematic review and meta-analysis. J Crohns Colitis 2014;8:93-106. [PMID: 23746864 DOI: 10.1016/j.crohns.2013.04.007] [Cited by in Crossref: 91] [Cited by in F6Publishing: 92] [Article Influence: 10.1] [Reference Citation Analysis]
|
| 34 |
Esteve R, Ramírez-maestre C. Pain Fear Avoidance and Pain Acceptance: A Cross-Sectional Study Comparing Their Influence on Adjustment to Chronic Pain Across Three Samples of Patients. ann behav med 2013;46:169-80. [DOI: 10.1007/s12160-013-9499-1] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 35 |
Rocchi A, Benchimol EI, Bernstein CN, Bitton A, Feagan B, Panaccione R, Glasgow KW, Fernandes A, Ghosh S. Inflammatory bowel disease: a Canadian burden of illness review. Can J Gastroenterol. 2012;26:811-817. [PMID: 23166905 DOI: 10.1155/2012/984575] [Cited by in Crossref: 174] [Cited by in F6Publishing: 194] [Article Influence: 17.4] [Reference Citation Analysis]
|
| 36 |
Vogelaar L, van't Spijker A, van Tilburg AJ, Kuipers EJ, Timman R, van der Woude CJ. Determinants of fatigue in Crohn's disease patients. Eur J Gastroenterol Hepatol 2013;25:246-51. [PMID: 23111414 DOI: 10.1097/MEG.0b013e32835aba83] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 2.9] [Reference Citation Analysis]
|
| 37 |
Kalafateli M, Triantos C, Theocharis G, Giannakopoulou D, Koutroumpakis E, Chronis A, Sapountzis A, Margaritis V, Thomopoulos K, Nikolopoulou V. Health-related quality of life in patients with inflammatory bowel disease: a single-center experience. Ann Gastroenterol 2013;26:243-8. [PMID: 24714279] [Reference Citation Analysis]
|
| 38 |
Jelsness-Jørgensen LP, Bernklev T, Henriksen M, Torp R, Moum B. Is patient reported outcome (PRO) affected by different follow-up regimens in inflammatory bowel disease (IBD)? A one year prospective, longitudinal comparison of nurse-led versus conventional follow-up. J Crohns Colitis 2012;6:887-94. [PMID: 22398072 DOI: 10.1016/j.crohns.2012.01.021] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 39 |
Rochelle TL, Fidler H. The importance of illness perceptions, quality of life and psychological status in patients with ulcerative colitis and Crohn’s disease. J Health Psychol 2013;18:972-83. [DOI: 10.1177/1359105312459094] [Cited by in Crossref: 34] [Cited by in F6Publishing: 39] [Article Influence: 3.1] [Reference Citation Analysis]
|
| 40 |
Hoivik ML, Moum B, Solberg IC, Cvancarova M, Hoie O, Vatn MH, Bernklev T; IBSEN Study Group. Health-related quality of life in patients with ulcerative colitis after a 10-year disease course: results from the IBSEN study. Inflamm Bowel Dis 2012;18:1540-9. [PMID: 21936030 DOI: 10.1002/ibd.21863] [Cited by in Crossref: 65] [Cited by in F6Publishing: 59] [Article Influence: 5.9] [Reference Citation Analysis]
|
| 41 |
Dudley-Brown S, Baker K. Ulcerative colitis from patients' viewpoint: a review of two Internet surveys. Gastroenterol Nurs 2012;35:54-63. [PMID: 22306730 DOI: 10.1097/SGA.0b013e318241d981] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 42 |
Ciccocioppo R, Klersy C, Russo ML, Valli M, Boccaccio V, Imbesi V, Ardizzone S, Porro GB, Corazza GR. Validation of the Italian translation of the Inflammatory Bowel Disease Questionnaire. Dig Liver Dis 2011;43:535-41. [PMID: 21315666 DOI: 10.1016/j.dld.2010.12.014] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 43 |
Fardet L, Petersen I, Nazareth I. Prevalence of long-term oral glucocorticoid prescriptions in the UK over the past 20 years. Rheumatology (Oxford) 2011;50:1982-90. [PMID: 21393338 DOI: 10.1093/rheumatology/ker017] [Cited by in Crossref: 165] [Cited by in F6Publishing: 181] [Article Influence: 13.8] [Reference Citation Analysis]
|
| 44 |
Liu FB, Li XY. Research of the quality of life of patients with ulcerative colitis: current status and future prospects. Shijie Huaren Xiaohua Zazhi 2011; 19(5): 498-504 [DOI: 10.11569/wcjd.v19.i5.498] [Reference Citation Analysis]
|
| 45 |
Mahic M, Skurtveit S, Selmer R, Rønning M, Furu K. Prevalence, incidence and persistence of etanercept and adalimumab in Norway 2005-2009: USE OF ETANERCEPT AND ADALIMUMAB IN NORWAY 2005-2009. Pharmacoepidem Drug Safe 2011;20:457-63. [DOI: 10.1002/pds.2091] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 46 |
Romberg-Camps MJ, Bol Y, Dagnelie PC, Hesselink-van de Kruijs MA, Kester AD, Engels LG, van Deursen C, Hameeteman WH, Pierik M, Wolters F, Russel MG, Stockbrügger RW. Fatigue and health-related quality of life in inflammatory bowel disease: results from a population-based study in the Netherlands: the IBD-South Limburg cohort. Inflamm Bowel Dis 2010;16:2137-47. [PMID: 20848468 DOI: 10.1002/ibd.21285] [Cited by in Crossref: 155] [Cited by in F6Publishing: 132] [Article Influence: 11.9] [Reference Citation Analysis]
|
| 47 |
Zhou Y, Ren W, Irvine EJ, Yang D. Assessing health-related quality of life in patients with inflammatory bowel disease in Zhejiang, China. J Clin Nurs. 2010;19:79-88. [PMID: 20500246 DOI: 10.1111/j.1365-2702.2009.03020.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 48 |
Ghosh S, Panaccione R. Anti-adhesion molecule therapy for inflammatory bowel disease. Therap Adv Gastroenterol 2010;3:239-58. [PMID: 21180606 DOI: 10.1177/1756283X10373176] [Cited by in Crossref: 80] [Cited by in F6Publishing: 89] [Article Influence: 6.2] [Reference Citation Analysis]
|
| 49 |
Eshuis EJ, Stokkers PC, Bemelman WA. Decision-making in ileocecal Crohn's disease management: surgery versus pharmacotherapy. Expert Rev Gastroenterol Hepatol 2010;4:181-9. [PMID: 20350265 DOI: 10.1586/egh.10.3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 50 |
Eshuis EJ, Slors JF, Stokkers PC, Sprangers MA, Ubbink DT, Cuesta MA, Pierik EG, Bemelman WA. Long-term outcomes following laparoscopically assisted versus open ileocolic resection for Crohn’s disease. Br J Surg. 2010;97:563-568. [PMID: 20175126 DOI: 10.1002/bjs.6918] [Cited by in Crossref: 114] [Cited by in F6Publishing: 122] [Article Influence: 8.8] [Reference Citation Analysis]
|
| 51 |
Bastida G, Nos P, Aguas M, Beltrán B, Iborra M, Ortiz V, Garrigues V, Estevan R, Ponce J. The effects of thiopurine therapy on health-related quality of life in Inflammatory Bowel Disease patients. BMC Gastroenterol. 2010;10:26. [PMID: 20196836 DOI: 10.1186/1471-230x-10-26] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 52 |
Hoivik ML, Bernklev T, Moum B. Need for standardization in population-based quality of life studies: a review of the current literature. Inflamm Bowel Dis 2010;16:525-36. [PMID: 19637337 DOI: 10.1002/ibd.21032] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 53 |
Vatn MH. Natural history and complications of IBD. Curr Gastroenterol Rep. 2009;11:481-487. [PMID: 19903424 DOI: 10.1007/s11894-009-0073-8] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 54 |
Oxelmark L. Quality of Life in Group-Based Intervention Program in Inflammatory Bowel Disease. Handbook of Disease Burdens and Quality of Life Measures 2010. [DOI: 10.1007/978-0-387-78665-0_193] [Reference Citation Analysis]
|
| 55 |
Wexner SD, Frattini JC. Quality of Life in Crohn’s Disease. Handbook of Disease Burdens and Quality of Life Measures 2010. [DOI: 10.1007/978-0-387-78665-0_127] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 56 |
Karwowski CA, Keljo D, Szigethy E. Strategies to improve quality of life in adolescents with inflammatory bowel disease. Inflamm Bowel Dis 2009;15:1755-64. [PMID: 19472359 DOI: 10.1002/ibd.20919] [Cited by in Crossref: 64] [Cited by in F6Publishing: 58] [Article Influence: 4.6] [Reference Citation Analysis]
|
| 57 |
Vogelaar L, Spijker AV, van der Woude CJ. The impact of biologics on health-related quality of life in patients with inflammatory bowel disease. Clin Exp Gastroenterol. 2009;2:101-109. [PMID: 21694833 DOI: 10.2147/ceg.s4512] [Cited by in Crossref: 52] [Cited by in F6Publishing: 57] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 58 |
Vergara M, Montserrat A, Casellas F, Maudsley M, Gallardo O, Ricart E, Calvet X. Validation of the Spanish Work Productivity and Activity impairment questionnaire: Crohn's disease version. Eur J Gastroenterol Hepatol 2009;21:809-15. [PMID: 19404204 DOI: 10.1097/MEG.0b013e32830f4c9e] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 59 |
Sadowski DC, Bernstein CN, Bitton A, Croitoru K, Fedorak RN, Griffiths A; CAG Crohn's Consensus Group. Canadian Association of Gastroenterology Clinical Practice Guidelines: The use of tumour necrosis factor-alpha antagonist therapy in Crohn's disease. Can J Gastroenterol 2009;23:185-202. [PMID: 19319383 DOI: 10.1155/2009/201430] [Cited by in Crossref: 26] [Cited by in F6Publishing: 32] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 60 |
Lix LM, Graff LA, Walker JR, Clara I, Rawsthorne P, Rogala L, Miller N, Ediger J, Pretorius T, Bernstein CN. Longitudinal study of quality of life and psychological functioning for active, fluctuating, and inactive disease patterns in inflammatory bowel disease. Inflamm Bowel Dis 2008;14:1575-84. [PMID: 18512245 DOI: 10.1002/ibd.20511] [Cited by in Crossref: 176] [Cited by in F6Publishing: 148] [Article Influence: 11.7] [Reference Citation Analysis]
|
| 61 |
Eshuis EJ, Bemelman WA, van Bodegraven AA, Sprangers MA, Bossuyt PM, van Milligen de Wit AW, Crolla RM, Cahen DL, Oostenbrug LE, Sosef MN, Voorburg AM, Davids PH, van der Woude CJ, Lange J, Mallant RC, Boom MJ, Lieverse RJ, van der Zaag ES, Houben MH, Vecht J, Pierik RE, van Ditzhuijsen TJ, Prins HA, Marsman WA, Stockmann HB, Brink MA, Consten EC, van der Werf SD, Marinelli AW, Jansen JM, Gerhards MF, Bolwerk CJ, Stassen LP, Spanier BW, Bilgen EJ, van Berkel AM, Cense HA, van Heukelem HA, van de Laar A, Slot WB, Eijsbouts QA, van Ooteghem NA, van Wagensveld B, van den Brande JM, van Geloven AA, Bruin KF, Maring JK, Oldenburg B, van Hillegersberg R, de Jong DJ, Bleichrodt R, van der Peet DL, Dekkers PE, Goei TH, Stokkers PC. Laparoscopic ileocolic resection versus infliximab treatment of distal ileitis in Crohn's disease: a randomized multicenter trial (LIR!C-trial). BMC Surg 2008;8:15. [PMID: 18721465 DOI: 10.1186/1471-2482-8-15] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 62 |
Irvine EJ. Quality of life of patients with ulcerative colitis: past, present, and future. Inflamm Bowel Dis 2008;14:554-65. [PMID: 17973299 DOI: 10.1002/ibd.20301] [Cited by in Crossref: 92] [Cited by in F6Publishing: 81] [Article Influence: 6.1] [Reference Citation Analysis]
|
| 63 |
Rutgeerts P, Schreiber S, Feagan B, Keininger DL, O'Neil L, Fedorak RN; CDP870 Crohn's Disease Study Group. Certolizumab pegol, a monthly subcutaneously administered Fc-free anti-TNFalpha, improves health-related quality of life in patients with moderate to severe Crohn's disease. Int J Colorectal Dis 2008;23:289-96. [PMID: 18071721 DOI: 10.1007/s00384-007-0395-7] [Cited by in Crossref: 41] [Cited by in F6Publishing: 45] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 64 |
Larsson K, Lööf L, Rönnblom A, Nordin K. Quality of life for patients with exacerbation in inflammatory bowel disease and how they cope with disease activity. J Psychosom Res 2008;64:139-48. [PMID: 18222127 DOI: 10.1016/j.jpsychores.2007.10.007] [Cited by in Crossref: 67] [Cited by in F6Publishing: 75] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 65 |
van der Woude CJ, Hommes DW. Are we ready for top-down therapy for inflammatory bowel diseases: pro. Expert Rev Gastroenterol Hepatol 2007;1:243-8. [PMID: 19072416 DOI: 10.1586/17474124.1.2.243] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 66 |
Jäghult S, Larson J, Wredling R, Kapraali M. A multiprofessional education programme for patients with inflammatory bowel disease: a randomized controlled trial. Scand J Gastroenterol 2007;42:1452-9. [PMID: 17852871 DOI: 10.1080/00365520701439685] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 67 |
Boye B, Jahnsen J, Lundin KEA, Wilhelmsen I, Malt UF, Jantschek G. Chronisch entzündliche Darmerkrankungen (Colitis ulcerosa und Morbus Crohn) aus der Perspektive der Konsiliar-/Liaison-Psychosomatik und -Psychiatrie. Psychosom Konsiliarpsychiatr 2007;1:258-265. [DOI: 10.1007/s11800-007-0026-8] [Reference Citation Analysis]
|
| 68 |
Ren WH, Lai M, Chen Y, Irvine EJ, Zhou YX. Validation of the mainland Chinese version of the Inflammatory Bowel Disease Questionnaire (IBDQ) for ulcerative colitis and Crohn's disease. Inflamm Bowel Dis 2007;13:903-10. [PMID: 17309070 DOI: 10.1002/ibd.20128] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 69 |
Calvet X, Gallardo O, Coronas R, Casellas F, Montserrat A, Torrejón A, Vergara M, Campo R, Brullet E. Remission on thiopurinic immunomodulators normalizes quality of life and psychological status in patients with Crohn's disease. Inflamm Bowel Dis 2006;12:692-6. [PMID: 16917223 DOI: 10.1097/00054725-200608000-00004] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 1.8] [Reference Citation Analysis]
|
